A 28-year-old man from Delhi presents with dysuria and purulent urethral discharge for 3 days. He reports unprotected sexual contact with a new partner 5 days ago. On examination, there is a thick, greenish-yellow urethral discharge and mild urethral tenderness. Gram stain of the urethral smear shows gram-negative intracellular diplococci within polymorphonuclear leukocytes. What is the most appropriate first-line treatment?

Explanation

## Diagnosis and Clinical Presentation **Key Point:** The clinical presentation of acute urethritis with thick, purulent discharge and Gram stain showing gram-negative intracellular diplococci is pathognomonic for *Neisseria gonorrhoeae* infection. **High-Yield:** The Gram stain finding of gram-negative intracellular diplococci (GNID) within PMNs is diagnostic for gonorrhea in symptomatic males. This is more sensitive and specific than culture in acute urethritis. ## Treatment Rationale | Feature | Ceftriaxone | Doxycycline | Ciprofloxacin | Azithromycin | |---------|-------------|-------------|---------------|---------------| | **Efficacy vs N. gonorrhoeae** | >99% | ~95% | Resistance emerging | ~95% | | **Dosing** | Single IM dose | 7 days oral | 3 days oral | Single dose | | **Resistance pattern** | Rare; still gold standard | Increasing resistance | High resistance (20–50%) | Increasing resistance | | **DOC status** | **WHO/CDC first-line** | Adjunctive only | Not recommended | Not recommended | | **Chlamydia coverage** | No | Yes | Yes | Yes | **Key Point:** Ceftriaxone 250 mg IM as a single dose is the current gold-standard first-line treatment for uncomplicated urogenital gonorrhea, recommended by WHO, CDC, and Indian STI guidelines. **Clinical Pearl:** Although fluoroquinolones (ciprofloxacin) were historically used, resistance rates now exceed 20–50% in many regions, making them unreliable. Doxycycline monotherapy is no longer recommended for gonorrhea due to emerging resistance; it is reserved as adjunctive therapy for concurrent chlamydial infection. **Warning:** Do NOT use azithromycin monotherapy for gonorrhea — resistance is rising and efficacy is unpredictable. Azithromycin is reserved for chlamydia or as part of combination regimens in resource-limited settings. ## Concurrent Chlamydia Coverage **High-Yield:** Up to 30–40% of patients with gonorrhea have concurrent *Chlamydia trachomatis* infection. Current guidelines recommend: - **Ceftriaxone 250 mg IM** (for gonorrhea) **+ Doxycycline 100 mg BD × 7 days** (for chlamydia) - OR Ceftriaxone + Azithromycin 1 g single dose (if doxycycline contraindicated) If the question asks for monotherapy, ceftriaxone alone is the answer for gonorrhea; dual therapy is standard practice in clinical settings. ## Why This Patient Needs Ceftriaxone 1. Gram stain confirms gonorrhea (GNID in PMNs) 2. Acute symptomatic urethritis with purulent discharge 3. Recent unprotected sexual exposure 4. Single-dose IM therapy ensures compliance 5. Covers resistant strains [cite:Harrison 21e Ch 137]